pemetrexed news

All news on pemetrexed (also known as Alimta and N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid): plants, production capacities, investments and involved companies.

30 July 2026

Johnson & Johnson: FDA Priority Review for potential first-in-class subcutaneous RYBREVANT FASPRO in recurrent/metastatic HNSCC

OrigAMI-4 showed 42% response rate with >1/3 complete responses; FDA review shortened to ~6 months; drug targets EGFR and MET and is co-formulated with hyaluronidase.
31 May 2026

Johnson & Johnson: RYBREVANT FASPRO shows durable responses in advanced head and neck cancer

Phase 1b/2 OrigAMI-4: subcutaneous amivantamab + hyaluronidase achieved 42% ORR (15% CR) in pretreated recurrent/metastatic HNSCC; median DOR not reached (11.8 mo FU); manageable safety.

Who will be producing pemetrexed in the future?

Find out with chemXplore Alpha

Learn more